Skip to main content
Clinical Trials/NCT04252391
NCT04252391
Unknown
Not Applicable

A Randomized Controlled Crossover Study to Determine the Effectiveness of Peri-Neural Electrical Dry Needling (PNED) vs. Standard Care for the Treatment of Patients With Migraine Headaches

Wheaton Franciscan Healthcare1 site in 1 country30 target enrollmentFebruary 18, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Migraine Headache
Sponsor
Wheaton Franciscan Healthcare
Enrollment
30
Locations
1
Primary Endpoint
Change in Neck disability index scale
Last Updated
3 years ago

Overview

Brief Summary

This study seeks to determine the effectiveness of a specific treatment protocol using dry needling with perineural electrical stimulation in comparison to standard treatment in physical therapy for patients with migraine headaches. This will be a randomized cross-over study in which participants will be in the first arm of the study, have a washout period, then cross over to the other arm of the study.

Detailed Description

From current understanding of migraine pathophysiology, the investigators know that it involves excitability of the trigeminovascular system. Intercranial vasculature containing nociceptor innervation consists of unmyelinated (c-fibers) and thinly myelinated (a-delta fibers ) axons which hold vasoactive neuropeptides including substance P and (CGRP) calcitonin gene related peptide. When a migraine occurs, there is a cortical spreading depolarization, which on a molecular level involves a release of ATP, glutamate, potassium, hydrogen ions, glia or vascular cells, and CGRP and nitric oxide by activated perivascular nerves. These substances, including CGRP diffuse to come in contact with nociceptors causing neurogenic inflammation (vasodilation), thus propagating a headache. Electrical perineural dry needling causes the release of substance-P and CGRG predominantly from non-neural structures, facilitating a negative feedback loop to neural and neuroactive components of the target tissue. This causes a lowering of the levels of CGRP which in turn decreases the inflammatory component thought to play a role in migraine headaches.

Registry
clinicaltrials.gov
Start Date
February 18, 2020
End Date
April 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Joseph Tepp

Principal Investigator

Wheaton Franciscan Healthcare

Eligibility Criteria

Inclusion Criteria

  • Men and women age 18 to 100 years old
  • Acute or chronic manifestation of migraine headaches or prior diagnosis of migraine headache.
  • Numeric pain rating of 3/10 (where 0= no pain and 10= worst pain)

Exclusion Criteria

  • History of epilepsy
  • Needle-phobia
  • Unstable psychological status
  • Compromised immune system
  • Metallic allergy
  • Having not eaten within the past 3 hours
  • Inability to lie in prone, or side-lying
  • Pregnant or trying to become pregnant
  • Inability to consent or understand English.
  • Prisoners

Outcomes

Primary Outcomes

Change in Neck disability index scale

Time Frame: 1-6 days

A functional status scale ranging from 0% to 100% (0%= no activity limitation, 100% =complete activity limitation). Participants will be assessed immediately before and after treatment. Participants will be assessed 2 days per week with a minimum of 1 day between treatment days.

Change in numeric pain rating scale

Time Frame: 1-6 days

Self reported pain intensity immediately before and after treatment using a numeric pain rating scale from 0 to 10 (0 = no pain and 10 = the worst pain). Participants will be assessed 2 days per week with a minimum of 1 day between treatment days.

Secondary Outcomes

  • Trends with use of perineural electrical dry needling with or without CGRP antagonist drugs.(following 4 weeks of treatment in the standard care plus perineural electrical dry needling arm.)

Study Sites (1)

Loading locations...

Similar Trials